Pipeline
PROGRAM
INDICATIONS
DISCOVERY
PRE-CLINICAL
PHASE 1/2
PIVOTAL
CAR-T (Allogeneic)
T-ALL/LBL
T-NHL
Autoimmune
T-ALL = T-cell Acute Lymphoblastic Leukemia
T-LBL = T cell Lymphoblastic Lymphoma
T-NHL = T-cell Non-Hodgkin’s Lymphoma
AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
T-LBL = T cell Lymphoblastic Lymphoma
T-NHL = T-cell Non-Hodgkin’s Lymphoma
AML = Acute Myeloid Leukemia
Lead Programs
WU-CART-007
Engineered to target T-cell cancers
- Opportunity to treat T-ALL, an orphan disease that presents in children, adolescents, and adults
- Deletion of the target in CAR-T prevents CAR-T Vs. CAR-T killing (friendly-fire)
- Disruption of the T-cell receptor enables the use of allogeneic donor T cells with reduced risk of Graft Vs. Host Disease
- Use of allogeneic donors prevents malignant cell contamination
- Clinical trials testing the safety and efficacy of WU-CART-007 are actively enrolling patients
Next in our story
Next in our story
Copyright © 2025 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design